Table 1

WHO classification of myeloid neoplasms and acute leukemia

WHO myeloid neoplasm and acute leukemia classification
Myeloproliferative neoplasms (MPN)
 Chronic myeloid leukemia (CML), BCR-ABL1+
 Chronic neutrophilic leukemia (CNL)
 Polycythemia vera (PV)
 Primary myelofibrosis (PMF)
  PMF, prefibrotic/early stage
  PMF, overt fibrotic stage
 Essential thrombocythemia (ET)
 Chronic eosinophilic leukemia, not otherwise specified (NOS)
 MPN, unclassifiable
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
 Myeloid/lymphoid neoplasms with PDGFRA rearrangement
 Myeloid/lymphoid neoplasms with PDGFRB rearrangement
 Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
 Chronic myelomonocytic leukemia (CMML)
 Atypical chronic myeloid leukemia (aCML), BCR-ABL1
 Juvenile myelomonocytic leukemia (JMML)
 MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
 MDS/MPN, unclassifiable
Myelodysplastic syndromes (MDS)
 MDS with single lineage dysplasia
 MDS with ring sideroblasts (MDS-RS)
  MDS-RS and single lineage dysplasia
  MDS-RS and multilineage dysplasia
 MDS with multilineage dysplasia
 MDS with excess blasts
 MDS with isolated del(5q)
 MDS, unclassifiable
Provisional entity: Refractory cytopenia of childhood
Myeloid neoplasms with germ line predisposition
Acute myeloid leukemia (AML) and related neoplasms
 AML with recurrent genetic abnormalities
  AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
  AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
  AML with t(6;9)(p23;q34.1);DEK-NUP214
  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
  Provisional entity: AML with BCR-ABL1
  AML with mutated NPM1
  AML with biallelic mutations of CEBPA
  Provisional entity: AML with mutated RUNX1
 AML with myelodysplasia-related changes
 Therapy-related myeloid neoplasms
  AML with minimal differentiation
  AML without maturation
  AML with maturation
  Acute myelomonocytic leukemia
  Acute monoblastic/monocytic leukemia
  Pure erythroid leukemia
  Acute megakaryoblastic leukemia
  Acute basophilic leukemia
  Acute panmyelosis with myelofibrosis
 Myeloid sarcoma
 Myeloid proliferations related to Down syndrome
  Transient abnormal myelopoiesis (TAM)
  Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemias of ambiguous lineage
 Acute undifferentiated leukemia
 Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
 MPAL with t(v;11q23.3); KMT2A rearranged
 MPAL, B/myeloid, NOS
 MPAL, T/myeloid, NOS
B-lymphoblastic leukemia/lymphoma
 B-lymphoblastic leukemia/lymphoma, NOS
 B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
 B-lymphoblastic leukemia/lymphoma with hyperdiploidy
 B-lymphoblastic leukemia/lymphoma with hypodiploidy
 B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
 B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21
T-lymphoblastic leukemia/lymphoma
Provisional entity: Early T-cell precursor lymphoblastic leukemia
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma